PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: GenScript Corporation

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

GenScript Launches GenPlus™ Next-Generation Gene Synthesis Technology, Achieving Monthly Gene Synthesis Capacity of 100 Mbp - GenScript has launched a new GenPlus™ Next-Generation Gene Synthesis service, which offers unmatched capacity and cost-efficiency for custom gene synthesis - GenScript.com
GenScript Launches GenPlus™ Next-Generation Gene Synthesis Technology, Achieving Monthly Gene Synthesis Capacity of 100 Mbp

 

NewswireToday - /newswire/ - Piscataway, NJ, United States, 2014/02/27 - GenScript has launched a new GenPlus™ Next-Generation Gene Synthesis service, which offers unmatched capacity and cost-efficiency for custom gene synthesis - GenScript.com. 1548:HK

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

GenScript, the world’s largest provider of synthetic genes, has launched a new GenPlus™ Next-Generation Gene Synthesis service, which offers unmatched capacity and cost-efficiency for custom gene synthesis.

Building upon over a decade of experience as the leading gene synthesis supplier in the US, GenScript has developed a new breakthrough technology: GenPlus™ Next-Generation Gene Synthesis. GenPlus™ combines the powers of parallel synthesis and automation to achieve a production capacity of over 100 million base-pairs per month, while maintaining GenScript’s commitment to providing 100% sequence fidelity and research-ready deliverables.

“We are very excited to launch this new platform of next generation gene synthesis. It catapults the global capacity of gene synthesis into a new level that has never before been reached,” said Frank Zhang, Ph.D., the CEO of GenScript. “We invite the world’s life science and biomedical research community to partner with us to explore the new research opportunities that are opened up with this unprecedented gene synthesis capacity.”

GenPlus™ offers an efficient high-capacity process that brings down the cost for research projects which require high-volume synthesis of hundreds or thousands of unique DNA sequences. As such, GenPlus™ expands researchers’ access to powerful research strategies. Large gene variant libraries enable efforts to engineer enzymes, metabolic circuits, genomes, and entirely new organisms. Rational design or random mutagenesis of DNA sequences can be used to systematically probe structure-function relationships and gene regulatory mechanisms. As a breakthrough in gene synthesis technology, GenPlus™ promises to spur innovation in disease therapeutics, agricultural technology, and energy, and to deepen our understanding the fundamental principles of biological systems.

About GenScript

Founded in 2002, GenScript (genscript.com) is a leading biology CRO specializing in customized biology research services including gene and peptide synthesis, protein expression, antibody generation and drug discovery/development. GenScript is headquartered in Piscataway, NJ, with subsidiaries in Europe, Japan, and China all dedicated to providing biology research services to 86 countries worldwide.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: GenScript Corporation

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


GenScript Launches GenPlus™ Next-Generation Gene Synthesis Technology, Achieving Monthly Gene Synthesis Capacity of 100 Mbp

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

GenScript | GenPlus™
Publisher Contact: Sally Wang - GenScript.com 
732-885-9188 sallyw[.]genscript.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GenScript Corporation securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From GenScript Corporation / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  Triggr & Bloom





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)